AlphaCrest Capital Management’s Twist Bioscience TWST Stock Holding History

AlphaCrest Capital Management’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,341	Closed	-$259K	–	1069
2022 Q3	$259K	Buy	+7,341	New	+$312K	0.02%	1180
2021 Q4	–	Sell	-5,060	Closed	-$541K	–	1445
2021 Q3	$541K	Buy	5,060 +1,657	+49%	+$190K	0.03%	877
2021 Q2	$453K	Buy	3,403 +803	+31%	+$93.4K	0.02%	984
2021 Q1	$322K	Buy	2,600 +600	+30%	+$91.1K	0.02%	994
2020 Q4	$283K	Buy	+2,000	New	+$222K	0.02%	941

Other funds holding TWST

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

AlphaCrest Capital Management's TWST Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Twist Bioscience (TWST) in Q4 2022, closing a stake of 7,341 shares — an estimated $259K sold.

AlphaCrest Capital Management first reported a position in TWST in Q4 2020 and held it in 5 quarters. The position peaked at $541K in Q3 2021. 199 funds tracked by Wall St. Rank hold TWST as of Q4 2022.

AlphaCrest Capital Management reported no remaining Twist Bioscience position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 7,341 Twist Bioscience shares in Q4 2022, an estimated $259K.
AlphaCrest Capital Management first reported a position in Twist Bioscience in Q4 2020 and held it in 5 quarters.
AlphaCrest Capital Management's Twist Bioscience position peaked at $541K in Q3 2021.
199 funds tracked by Wall St. Rank held Twist Bioscience as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.